Therefore, to develop a therapeutic strategy that could provide an improvement in the treatment of advanced HCC without increased toxicity, we investigated the effects of combina-tions of biochanin A with the BRAF inhibitor SB590885 on anti-proliferative and survival pathways in HCC cells in vitro and in vivo. This evidence concerns the gene BRAF and hepatocellular carcinoma.